The trajectory of companies tied to the drug's history presents a challenging investment scenario . While the initial surge generated substantial returns , generic copies have significantly diminished revenue. Investing in associated pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving patient shifts ,